NasdaqGS:ALMSPharmaceuticals
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders
Earlier in August 2026, Alumis Inc. reported second-quarter results showing revenue of US$1.66 million and a net loss of US$142.22 million, reversing a net profit a year earlier as loss per share widened sharply.
A few days before that earnings release, Alumis reported positive topline Phase 3 ONWARD3 extension data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis and outlined plans to file a U.S. FDA New Drug Application this year, highlighting a potential first-in-class,...